Allergy/Imm

sponsor
Become a Member Today!
Register
Email:


Password:

Remember me
Forgot your Password?
Invite Code?
Article ID

Your Article Summary

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Romero AI et al. – A recent phase III study has demonstrated that post–consolidation treatment with the combination of histamine dihydrochloride (HDC) and IL–2 significantly prevents relapse in AML patients. Here the authors account for the preclinical background to the use of HDC/IL–2 in AML along with a review of clinical results.


Sponsor

Article Search

Keyword:

Search:

Published within

Sort By:
Date
Relevance


Sponsor

Sponsor

Send this Summary to a Colleague

Enter email address